CALT: Calliditas Analyst Consensus Forecast

Calliditas Therapeutics operates within an autonomous product cycle, rendering the business resilient to global economic fluctuations and a reliable asset. The market price of 45.63, as confirmed by the chart, correlates with the company's exceptional pricing power over Tarpeyo, the first targeted therapy for slowing renal failure. Global presence is secured through partnerships with STADA and Everest Medicines for distribution across Europe and Asia.

Calliditas Therapeutics - CALT Consensus Target (period 07/04/2022 - 09/28/2024)

Analytical breakdowns for Calliditas Therapeutics (CALT)

- market price and analyst price targets:

Stock Quotes calliditas.se|CALT - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization Calliditas|CALT - Total Company Value

- balance sheet equity data:

Net Assets per Single Share Calliditas Therapeutics|CALT - Company Net Assets|Market Cap to Book Value Multiple calliditas.se|CALT - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

Aggregate Debt to Equity Calliditas Therapeutics|CALT - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital calliditas.se|CALT - Company Aggregate Debts|Debts to Book Capitalization Calliditas|CALT - Company Long-Term Debt|Company Short-Term Loans and Borrowings Calliditas Therapeutics|Quick Liquidity Indicator calliditas.se

- financial results and valuation multiples details:

CALT - Net Profit|Projected Future Earnings Calliditas Therapeutics|CALT - Price to Earnings Ratio|Future Price to Earnings Multiple calliditas.se|CALT - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Calliditas|CALT - Operating profit EBITDA|Net earnings per share for the last four quarters Calliditas Therapeutics|CALT - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months calliditas.se|CALT - Earnings per share growth in current year|Projected earnings per share growth rate for next year Calliditas Therapeutics

General company analysis:CALT Calliditas Therapeutics, Inc.

Flagship merchandise of Calliditas Therapeutics AB

Stable demand for the treatment of renal pathologies provides Calliditas Therapeutics (CALT) with high macro-resilience, minimizing the impact of market cyclicality. Daily recalculations of the weighted average expert valuation allow for the prompt capture of shifts in fundamental expectations, which helps investors identify market equilibrium points via the consensus valuation chart, despite persisting risks of short-term price drawdowns.

Competitors of Calliditas Therapeutics